China-based BeiGene's RAF dimer inhibitor, lifirafenib, is being assessed in combination with SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in a phase 1b clinical trial in patients with advanced solid tumours, it was reported Friday.
The companies have signed a global clinical collaboration contract to evaluate the safety, tolerability and preliminary efficacy of this combination. BeiGene will have responsibility for administering the early-stage trial, which is expected to start during the first quarter of 2019.
BeiGene stated that the inhibitor showcased antitumor activities in preclinical models and in cancer patients with tumours harbouring BRAF V600E mutations, non-V600E BRAF mutations and also non-small cell lung cancer and endometrial cancer harbouring KRAS mutations. PD-0325901, which inhibits MEK, has been demonstrated in clinical biopsies to block MEK phosphorylation, leading to cell death.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review